Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors

por Tsimberidou, Apostolia Maria, Verschraegen, Claire F., Wesolowski, Robert, Shia, Chi-Sheng, Hsu, Pei, Pearce, Tillman E.
Publicado 2023

First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

por Tsimberidou, Apostolia Maria, Vo, Henry Hiep, Beck, Jennifer, Shia, Chi-Sheng, Hsu, Pei, Pearce, Tillman E.
Publicado 2023